• Lantern Pharma published a clinical update on LP-300 in EGFR exon 21 L858R-mutant non-small cell lung cancer from its HARMONIC Phase 2 trial.
• Preliminary L858R cohort results showed median progression-free survival of 8.4 months with durable responses beyond 2 years in select patients.
• Clinical benefit rate in the L858R cohort was 77%.
• FDA Type C feedback raised no objections to enriching enrollment for L858R, extending LP-300 dosing to 8 cycles, shifting to a single-arm design.
• Safety summary showed 3% treatment-related serious adverse events for LP-300 with chemotherapy, versus 23% reported for amivantamab with chemotherapy in MARIPOSA-2.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantern Pharma Inc. published the original content used to generate this news brief on June 02, 2026, and is solely responsible for the information contained therein.